This prospective study shows that the rate of azole resistant Aspergillus fumigatus (ARAF) in Indian immunocompromised patient population with invasive aspergillosis (IA) is low, 6/706 (0.8%). This lower rate supports the continued use of voriconazole as the first line of treatment. However, the ARAF in this study exhibited three kinds of unreported cyp51A mutations from India, of which two were at hot spots, G54R and P216L while one was at codon Y431C.
https://ift.tt/2LHNRvN
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου